The Pharma CEO Aiming to Beat Obesity — and Ozempic: Leader Q&A

Welcome to the latest edition of our interview series that focuses on how today’s leaders are thinking ahead.

Adam Steensberg, 49, a doctor by training, worked at drugmaker Novo Nordisk A/S before joining Zealand Pharma A/S and becoming CEO in 2022. Since he took the helm, the Danish drugmaker’s market value has increased nine-fold as Steensberg focuses on developing a promising obesity treatment to compete with blockbuster drugs like Novo’s Ozempic and Eli Lilly & Co.’s Zepbound. He sat down with Bloomberg to discuss the obesity crisis, how businesses should respond to it, and why he’s reading about man’s search for meaning. The transcript has been edited ...